ANI Pharmaceuticals Inc (ANIP)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 144,861 | 221,121 | 48,228 | 100,300 | 7,864 |
| Short-term investments | US$ in thousands | 6,307 | — | — | — | — |
| Total current liabilities | US$ in thousands | 193,680 | 145,477 | 99,439 | 87,537 | 78,565 |
| Cash ratio | 0.78 | 1.52 | 0.49 | 1.15 | 0.10 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($144,861K
+ $6,307K)
÷ $193,680K
= 0.78
The cash ratio of ANI Pharmaceuticals Inc has shown fluctuations over the past five years. As of December 31, 2020, the cash ratio was 0.10, indicating that the company had only 10% of its current liabilities covered by cash. However, by December 31, 2021, the cash ratio improved significantly to 1.15, suggesting a more comfortable liquidity position with 115% of current liabilities covered by cash.
In the following years, the cash ratio continued to vary. By December 31, 2022, the ratio had decreased to 0.49, signaling a potential decrease in liquidity compared to the previous year. Subsequently, by December 31, 2023, the cash ratio rose notably to 1.52, reflecting a robust liquidity position with 152% of current liabilities covered by cash.
However, by December 31, 2024, the cash ratio fell to 0.78, indicating a slight decrease in liquidity compared to the previous year. Overall, the cash ratio trend for ANI Pharmaceuticals Inc displays fluctuations in liquidity levels over the five-year period, with some years showing stronger liquidity positions than others.
Peer comparison
Dec 31, 2024